Anti-CD137 Antibody [4B4-1] (A279352)

Anti-CD137 Antibody [4B4-1]

Mouse monoclonal [4B4-1] antibody to CD137.

This antibody recognises CD137. CD137 (also known as 4-1BB ligand receptor or TNFRSF9) is a type I transmembrane glycoprotein of the Tumor Necrosis Factor receptor family that is expressed on activated T and NK cells, dendritic cells, myeloid cells and at the surface of some non-lymphoid cells under specific conditions. CD137 acts as a receptor for 4-1BB ligand, expressed on activated macrophages, activated B cells, hematopoietic stem cells and myeloid progenitor cells and for some proteins of the extracellular matrix. The interaction between CD137 and 4-1BBL acts as a co-stimulatory signal for the activation, expansion and survival of T cells. CD137 signaling is involved in the generation of CD8+ T cells and enhance their cytotoxic activity. Because of its ability to promote the anti-tumorigenic activity of cytotoxic T cells, CD137 is the target of several cancer immune therapies, such as the agonist anti-CD137 Urelumab and Utomilumab. CD137 also binds to the adaptor proteins TRAF1, 2 and 3 to promote NF-kappaB activation. Mouse anti-human CD137, clone 4B4-1 has been reported to immunoprecipitate a homodimeric protein of 32kDa under reducing conditions and 85kDa under non-reducing conditions.

Flow Cytometry, IP, ELISA, Functional Assays

Human, Primate

Recombinant human CD137 ectodomain.

Mouse

Monoclonal

4B4-1

IgG1

Protein A affinity chromatography of tissue culture supernatant.

>95% (by SDS-PAGE).

Liquid

Supplied in Phosphate Buffered Saline with <0.1% Sodium Azide.

Store undiluted at 4°C. Do not freeze!

Mouse anti Human CD137, clone 4B4-1 recognizes CD137. CD137 (also known as 4-1BB ligand receptor or TNFRSF9) is a type I transmembrane glycoprotein of the Tumor Necrosis Factor receptor family that is expressed on activated T and NK cells, dendritic cells, myeloid cells and at the surface of some non-lymphoid cells under specific conditions (Schwarz et al. 1995). CD137 acts as a receptor for 4-1BB ligand, expressed on activated macrophages, activated B cells, hematopoietic stem cells and myeloid progenitor cells (Pollock et al. 1994) and for some proteins of the extracellular matrix (Chalupny et al. 1992).The interaction between CD137 and 4-1BBL acts as a co-stimulatory signal for the activation, expansion and survival of T cells (Wen et al. 2002). CD137 signaling is involved in the generation of CD8+ T cells and enhance their cytotoxic activity (Shuford et al. 1997). Because of its ability to promote the anti-tumorigenic activity of cytotoxic T cells, CD137 is the target of several cancer immune therapies, such as the agonist anti-CD137 Urelumab (Segal et al. 2017) and Utomilumab (Chester et al. 2018). CD137 also binds to the adaptor proteins TRAF1, 2 and 3 to promote NF-kappaB activation (Jang et al. 1998).Mouse anti-human CD137, clone 4B4-1 has been reported to immunoprecipitate a homodimeric protein of 32kDa under reducing conditions and 85kDa under non-reducing conditions (Garni-Wagner et al. 1996).

4-1BB ligand receptor, CDw137, ILA, T-cell antigen 4-1BB homolog, T-cell antigen ILA, TNFRSF9, Tumor necrosis factor receptor superfamily member 9